雷贝拉唑三联疗法在萎缩性胃炎并发幽门螺杆菌感染患者中的应用效果

发布时间：2019-03-07 23:04

【摘要】：目的探讨雷贝拉唑三联疗法在萎缩性胃炎并发幽门螺杆菌(Hp)感染患者中的应用效果。方法 164例萎缩性胃炎并发Hp感染患者随机分为三联疗法组和对照组,每组各82例;对照组采用雷贝拉唑进行治疗,三联疗法组采用雷贝拉唑、阿莫西林与呋喃唑酮三联疗法进行治疗,对比两组萎缩性胃炎并发Hp感染患者疗效、血清丙二醛(MDA)水平、血清超氧化物歧化酶(SOD)水平及谷胱甘肽过氧化物酶(GSH-PX)活性、不良反应。结果治疗前,两组萎缩性胃炎并发Hp感染患者血清MDA、SOD、GSH-PX水平差异无统计学意义;治疗后,两组萎缩性胃炎并发Hp感染患者血清MDA水平均显著降低,SOD、GSH-PX水平均显著升高(P0.01);与对照组相比,三联疗法组患者血清MDA水平显著低于对照组,SOD、GSH-PX水平均显著高于对照组(P0.05);三联疗法组患者治疗总有效率为95.1%,显著高于对照组的82.9%,差异有统计学意义(P0.01);三联疗法组患者治疗后Hp转阴率为92.7%,显著高于对照组的79.3%,差异有统计学意义(P0.05);三联疗法组患者治疗后不良反应发生率为7.3%,对照组为8.5%,两组比较差异无统计学意义。结论雷贝拉唑三联疗法能够显著提升萎缩性胃炎并发Hp感染患者的治疗有效率及Hp转阴率,可能与MDA水平降低,SOD、GSH-PX水平均升高有关。
[Abstract]:Objective to investigate the effect of Rabeprazole triple therapy in patients with atrophic gastritis complicated with Helicobacter pylori (Hp) infection. Methods A total of 164 patients with atrophic gastritis complicated with Hp infection were randomly divided into two groups: control group (n = 82) and triple therapy group (n = 82). The control group was treated with rabeprazole, and the triple therapy group was treated with rabeprazole, amoxicillin and furazolidone. The curative effect and the level of malondialdehyde (MDA) in patients with atrophic gastritis complicated with Hp infection were compared between the two groups. Serum superoxide dismutase (SOD) level and glutathione peroxidase (GSH-PX) activity, adverse reactions. Results before treatment, there was no significant difference in the level of serum MDA,SOD,GSH-PX between the two groups of patients with atrophic gastritis complicated with Hp infection. After treatment, the level of serum MDA in patients with atrophic gastritis complicated with Hp infection was significantly decreased and the level of SOD,GSH-PX was significantly increased (P0.01). Compared with the control group, the serum MDA level in the triple therapy group was significantly lower than that in the control group, while the SOD,GSH-PX level was significantly higher than that in the control group (P0.05). The total effective rate of the triple therapy group was 95.1%, which was significantly higher than that of the control group (82.9%), the difference was statistically significant (P0.01). After treatment, the negative rate of Hp in the triple therapy group was 92.7%, which was significantly higher than that in the control group (79.3%), the difference was statistically significant (P0.05). The incidence of adverse reactions was 7.3% in the triple therapy group and 8.5% in the control group. There was no significant difference between the two groups. Conclusion Rabeprazole triple therapy can significantly improve the effective rate and the negative rate of Hp in patients with atrophic gastritis complicated with Hp infection, which may be related to the decrease of MDA level and the increase of SOD,GSH-PX level.
【作者单位】：天津市第五中心医院健康体检科;天津市第五中心医院消化内科;天津市第五中心医院感染科;
【基金】：天津市卫生局医药科技计划基金资助项目(TJ20154536)
【分类号】：R573.32

【相似文献】